Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.68 |
| ▸ | KDR | P35968 | 8/20 | 0.48 |
| ▸ | FLT1 | P17948 | 4/20 | 0.48 |
| ▸ | RET | P07949 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.46 |
| ▸ | FLT4 | P35916 | 2/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.44 |
| ▸ | CIT | O14578 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18013029 | 0.86 | EGFR (0.69) | EGFRKDRFLT1RETHDAC3 | |
| SCHEMBL18013020 | 0.85 | KDR (0.59) | EGFRKDRFLT1RETHDAC3 | |
| SCHEMBL5864606 | 0.81 | EGFR (1.00) | EGFRKDRFLT1RETFGFR1 | |
| SCHEMBL18013028 | 0.81 | EGFR (0.56) | EGFRKDRGAKKDM1AERBB2 | |
| SCHEMBL18012083 | 0.80 | KCNH2 (0.63) | EGFRKDRFLT1ERBB2EPHB4 | |
| SCHEMBL19885271 | 0.80 | KDR (0.54) | EGFRKDRFLT1RETHDAC3 | |
| SCHEMBL18013058 | 0.80 | EGFR (0.59) | EGFRKDRFLT1RETFLT4 | |
| SCHEMBL18013053 | 0.78 | RET (0.53) | EGFRKDRFLT1RETFGFR1 | |
| SCHEMBL19885289 | 0.77 | KDR (0.61) | EGFRKDRFLT1RETHDAC3 | |
| SCHEMBL17967506 | 0.77 | FLT1 (0.77) | EGFRKDRFLT1FLT4FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| WO-2016123706-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | EGFR, ERBB2, ERBB4 | EGFR 1/4885KDR 339/4885FLT1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.